SK Biotechnology, Nova Boxes Corona 19 Vaccine Contracting Extension Contract

Immunity is a life scientific researches business that concentrates on immunotherapy.

SK Bio Science has been able to expand the contract for Corona 19 vaccine consignment.

SK Bios hi, announced on the 24th that the Corona 19 vaccine 'NVX-COV2373' developed by Nova Boxes developed by the US Biobío Bags and the CMO (consignment production) and license agreement for global supply.

The contract period is until December next year, SK Bishops will use three among NVX-COV2373 production of the nine source production facilities of the An dong vaccine factory L House.

The contract is a method of selling a sales fee due to the production fee due to the production of the Nova Box (DS) from November (DS) production (DS) and the sales fee due to the sale of Novae (DP). And it was signed.

The Source Agreement has been consulted by the form of SK Biotechnology, according to the production of Nova Boxes. In addition, the finished contract was that when Nova Boxing was prepared in one of the Orthodox Production facilities of the An dong, SK Biotechnology received a commission according to sales.

SK Bosnian was able to pursue the NVX-COV2373 produced in An dong, and the right to supply and commercialize in Thailand and Vietnam, and to pursue a purchase agreement for each country.

SK Biotechnology is expected to explore additional sales by each contract, including about 2.2 billion won, including the expected fee to be generated according to the amount of liquidity.

Stanley ERCK (Stanley ERIK) CEO said, We are a very important partner for the SK Biotechnology and Korea to supply Corona 19 vaccines around the world. This collaboration expands the global network for commercialization of high quality products. We will contribute to the goal of producing the partners and the vaccine of 20 billion Doll.

This Agreement is another meaningful achievement, which is another meaningful achievement that SK Bios hi, and a global level of vaccine production capacity, said SK Bishops, said, At the same time, we will try to achieve the co-goal of the protection of the vulnerable population through the fair vaccine supply.

SK Bishops has been a license agreement, including Nova Bags, August, and February this year, and has established a license agreement, including the February, and the NVX-COV2373 production has been conducted. This completes all preparations for commercial production by completing the protein-based nanoparticle recombination and production process technology required for NVX-COV2373 production.

NVX-COV2373 is a long period of use in existing vaccines, such as influenza (flu), hepatitis, and cervical cancer vaccine, and is developed in a synthetic antigen method, which is a platform, which is proven to be safe and efficiency. It can be kept in a refrigeration condition of 2 to 8 degrees, so that it can be used to utilize existing vaccine logistics networks and is unnecessary of the process of thawing in the inoculation step.

Nova Bags's own clinical effects of NVX-COV2373 were also confirmed, and in clinical trials that have been conducted in the clinical trials that were conducted on US and 3,000 adults over 18 years of age or older in Mexico, 90% of NVX-COV2373 Most of the responses occurring after vaccination were mild or moderate due to mild or moderate.

No vagus is in the United States, in the United States, conducting clinical 3-year-to-year-to-thirds, and is in vaccination age, and NVX-COV2373 is inoculated twice, 6 months later, I also released a 4.6x increase of data.

In recent studies in which Nova Boxes conducted, the immune response of NVX-COV2373 for Omit on and other mutant viruses. The NVX-COV2373 was inoculated twice and inoculated with a booster shot after six months later, and the antibody that responds to the reconciliation of the Omit on mutation was 9.3 times the second inoculation, and the delta variation was 11.1 times higher.

Meanwhile, SK Biotechnology is attracting attention as a global vaccine production base and a collaborative request for domestic and international private institutions to develop and produce corona 19 vaccines.

In July, last year, I have signed a CMO agreement to commission the abandoned by AstraZeneca and Corona 19 vaccine, and in August, in August, Novas Bags and Corona 19 vaccine in August Consignment contracts have been made to have a contract with the contract, and have been transferred exclusively in Korea exclusively in Korea.

In October, CPI's facility usage contract was signed a contract for extending the contract by the end of 2022, which to expand the contract with No vagus, and continued a cooperation for a successful three-party partnership.

The Donna 19 vaccine manufacturing facility, an An dong L House, an SK Bios hi, a vaccine factory, has obtained EU-GMP (excellent medicines manufacturing and quality control standards) and has been recognized in the world of manufacture and quality control. In addition, it is a plan to continue to expand the CMO business and establishes a global vaccine herbalist by establishing an expansion of the L house and establishing a new R & PD center.